Abstracts tagged "SLE and biomarkers"

Abstract Number: 2538 • 2019 ACR/ARP Annual Meeting
Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous
Tetsuji Sawada¹, Makoto Kurano ², Harumi Shirai ³, Yukiko Iwasaki ³, Koichiro Tahara ¹, Haeru Hayashi ¹, Koji Igarashi ⁴, Keishi Fujio ⁵, Junken Aoki ⁶ and Yutaka Yatomi ⁷, ¹Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ²Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Bioscience Division, Research and Development Management Department, TOSOH Corporation, Kanagawa, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, ⁶Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, ⁷Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Phosphatidylserine-specific phospholipase A1 (PS-PLA1) is a secreted lipase that is proposed to be a producing enzyme for lysophosphatidylserine (LysoPS), which is an emerging lipid…
Abstract Number: 1664 • 2017 ACR/ARHP Annual Meeting
Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients
Kamala Vanarsa¹, Samar Soliman², Aubrey Swilling³, Joan T. Merrill⁴ and Chandra Mohan², ¹Biomedical Engineering, University of Houston, houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³University of Houston, houston, TX, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-systemic autoimmune disease, with a broad spectrum of clinical manifestations and unpredictable disease course with periods of…
Abstract Number: 78 • 2016 ACR/ARHP Annual Meeting
Whole Blood Gene Modules Show Differences Between Active Lupus Nephritis and Quiescent Disease As Well As Absence of Plasmablast Signature in This Adult Population
Eric Zollars¹, Gerard Hardiman², Bethany Wolf³, Sean Courtney⁴, Norm Allaire⁵, Ann Ranger⁶ and Michelle Petri⁷, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵BiogenIdec, Cambridge, MA, ⁶Unum RX, Cambridge, MA, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: SLE is a complex disease with heterogeneous manifestations. It seems unlikely that all patients labeled as SLE have homogenous molecular pathology. An approach…
Abstract Number: 2847 • 2016 ACR/ARHP Annual Meeting
Antibodies to Double Stranded DNA: Combined Standard ELISA and High-Salt ELISA Assays for the Detection of SLE Disease Activity
Laura Durcan, Jenna Thomason, Daniel Kuo and Mark H. Wener, University of Washington, Seattle, WA
Background/Purpose: Serological markers in systemic lupus erythematosus (SLE) are crucial objective measures included in disease activity indices. Antibodies to double stranded DNA (anti-dsDNA) are included…
Abstract Number: 777 • 2015 ACR/ARHP Annual Meeting
SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
D. Scott Batty¹, I.R. Cohen², Chaim Putterman³, Nicole Jordan⁴, Keren Jakobi⁵, Rachel Sorek⁵, Yakov Blumenstein⁵, Pennina Safer⁵ and David Pisetsky⁶, ¹ImmunArray Inc., Richmond, VA, ²Weizmann Institute of Science, Rehovot, Israel, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel, ⁶Duke University Medical Center and Durham VAMC, Durham, NC
Background/Purpose: SLE is associated with a broad spectrum of autoantibodies, but currently there is no single serologic test to diagnose SLE definitively. Diagnosis is thus…
Abstract Number: 818 • 2015 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products (CB-CAP) Profiles in Patients with Pre-Systemic Lupus Erythematosus
Chau-Ching Liu¹, Xizoqin Tang², Susan Manzi³ and Joseph Ahearn⁴, ¹Allegheny Singer Research Institute, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA, ⁴Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: The onset of SLE, a prototypical autoimmune disease characterized by immune dysregulation and consequential inflammatory tissue injury, may be insidious with non-specific symptoms. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].